The metabolic drug market faces unprecedented structural capacity constraints, forcing pharmaceutical leaders to dramatically scale global fill-finish assembly operations.
Contract Manufacturing Demand Surge
Sterile injectable manufacturing capacity remains the primary bottleneck for anti-obesity therapeutics. Top producers are locking in multi-year dedicated capacity agreements with third-party contract development and manufacturing organizations while building proprietary manufacturing facilities worldwide.